BCR and chronic myelogenous leukemia, BCR-ABL1 positive: To optimize therapeutic strategies and improve remission rates in CML, several second-generation BCR::ABL1tyrosine kinase inhibitors (TKIs), including nilotinib, dasatinib, ponatinib, and bosutinib, have been successfully developed (Sampaio et al., 2021; Tian et al., 2018).